Drug response prediction in high-risk multiple myeloma

Gene 644 (2018) 80-86

Molecular prediction of adjuvant cisplatin efficacy in Non-Small Cell Lung Cancer (NSCLC) - validation in two independent cohorts

PloS One 2018;10.1371


Retrospective-prospective blinded evaluation predicting efficacy of epirubicin by a multigene assay in advanced breast cancer within a Danish Breast Cancer Cooperative Group (DBCG) cohort.

Abstract at ASCO 2017


Prospective blinded evaluation predicting efficacy of adjuvant cisplatinum and vinorelbine by a multigene assay after radical surgery in non-small cell lung cancer.

Poster at ESMO 2016 Congress

Fulvestrant response prediction from transcriptome data obtained from primary breast cancer biopsies

Abstract at ASCO 2016

Cell Line Derived 5-FU and Irinotecan Drug-Sensitivity Profiles Evaluated in Adjuvant Colon Cancer Trial Data

PLOS ONE | DOI:10.1371/journal.pone.0155123 May 12, 2016

Clinical Impact of a Novel MicroRNA Chemo-Sensitivity Predictor in Gastrooesophageal Cancer

PLOS ONE | DOI:10.1371/journal.pone.0148070 February 17, 2016


Development and blind clinical validation of a microRNA based predictor of response to treatment with R-CHO(E)P in DLBCL.

PLOS ONE | DOI:10.1371/journal.pone.0115538 February 18, 2015


Development and Validation of a Gene Expression Score That Predicts Response to Fulvestrant in Breast Cancer Patients.

PLOS ONE | DOI:10.1371/journal.pone.0087415 February 5, 2014


Cell-free plasma microRNA in pancreatic ductal adenocarcinoma and disease controls.

PubMed | DOI:10.1097/MPA.0b013e318296bb34, October, 2013

Independent Validation of a Model Using Cell Line Chemosensitivity to Predict Response to Therapy.

JOURNAL of the NATIONAL CANCER INSTITUTE | DOI:10.1093/jnci.djt202, August 20, 2013


Belinostat in AML

Poster at ESMO 2012 Congress


A 71-gene signature of TRAIL sensitivity in cancer cells..

Junjie Chen, Steen Knudsen, Wiktor Mazin, Jesper Dahlgaard, and Baolin Zhang. Published Published OnlineFirst October 25, 2011; doi: 10.1158/1535-7163.MCT-11-0620

Analytical variables influencing the performance of a miRNA based laboratory assay for prediction of relapse in stage I non-small cell lung cancer (NSCLC)..

Jesper Dahlgaard, Wiktor Mazin, Thomas Jensen, Mette Pøhl, Wiam Bshara6, Anker Hansen, Eric Kanisto, Stephen Jacques Hamilton-Dutoit, Olfred Hansen, Henrik Hager, Henrik J Ditzel, Sai Yendamuri, and Steen Knudsen. Published 19 October 2011

Market access challenges in the EU for high medical value diagnostic tests.

Iain Miller†1,2, Joanna Ashton‐Chess, Herman Spolders, Vincent Fert, Joseph Ferrara, Werner Kroll1,7,Jon Askaa,Patrick Larcier, Patrick F Terry, Anne Bruinvels & Alain Huriez1. Published 10.2217/PME.11.2 © 2011 Future Medicine Ltd


Evaluation of microRNA expression profiles that may predict recurrence of localized stage I non-small cell lung cancer after surgical resection..

Patnaik SK1, Kannisto E, Knudsen S, Yendamuri S. Published 2010 Jan 1;70(1):36-45. doi: 10.1158/0008-5472.CAN-09-3153. Epub 2009 Dec 22.